Quanterix Corporation reports results for the quarter ended June 30 - Earnings Summary
Quanterix Corporation reports results for the quarter ended June 30 - Earnings Summary
Quanterix Corporation QTRX.OQ reported a quarterly adjusted loss of $1.04 per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -57 cents. The mean expectation of three analysts for the quarter was for a loss of 46 cents per share. Wall Street expected results to range from -47 cents to -45 cents per share.
Revenue rose 34.4% to $32.91 million from a year ago; analysts expected $37.46 million.
Quanterix Corporation's reported EPS for the quarter was a loss of $1.04.
The company reported a quarterly loss of $48.93 million.
Quanterix Corporation shares had fallen by 6.7% this quarter and lost 36.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 14.1% in the last three months.
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Quanterix Corporation is $4.00, about 0.8% below its last closing price of $4.03
This summary was machine generated from LSEG data August 10 at 01:32 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.46 | -1.04 | Missed |
Mar. 31 2026 | -0.54 | -0.37 | Beat |
Dec. 31 2025 | -0.45 | -0.49 | Missed |
Sep. 30 2025 | -0.53 | -0.73 | Missed |
Recent news on Quanterix
See all newsBrief: Alzpath And Quanterix Expand Strategic Licensing Agreement To Advance Next Generation Alzheimer's Disease Biomarker Research
Quanterix Corporation reports results for the quarter ended June 30 - Earnings Summary
Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Quanterix Corporation expected to post a loss of 46 cents a share - Earnings Preview
Quanterix Corp expected to post a loss of 46 cents a share - Earnings Preview